Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Evolus
< Previous
1
2
3
4
Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
July 09, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolysse™ Recognized in 2025 Shape Skin Awards
June 10, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Departure of its Chief Financial Officer
May 27, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
May 22, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports First Quarter 2025 Results
May 07, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
May 05, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report First Quarter Financial Results on May 7, 2025
April 23, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Commercial Launch of Evolysse™
April 16, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
April 15, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
March 25, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
March 04, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
February 27, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
February 20, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
February 18, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
February 13, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
January 21, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Third Quarter 2024 Results
November 06, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in Stifel 2024 Healthcare Conference
November 01, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
October 31, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Third Quarter Financial Results on November 6, 2024
October 23, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 27, 2024
From
Evolus
Via
Business Wire
Tickers
EOLS
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
